Actively Recruiting
Intravenous Versus Oral Treatment of the Main Acute Infections
Led by University of Southern Denmark · Updated on 2026-03-05
4000
Participants Needed
7
Research Sites
155 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients admitted to the hospital with acute infections are often treated with intravenous (IV) antibiotics. Around 70% of these infections fall into three categories: respiratory tract infections, urinary tract infections, and cellulitis. A Danish study found that 76% of patients admitted with suspected community-acquired pneumonia and treated with antibiotics received them intravenously. Based on an extrapolated estimate from an unpublished local survey, approximately 50,000 patients in Denmark are admitted each year for infections and treated with IV antibiotics. The average hospital stay for these patients is 5.9 days, resulting in a total of 295,000 hospital days annually, accounting for about 7% of total hospital admissions in Denmark. This represents an annual cost of 2.3 billion DKK. While some patients need hospitalization due to their overall health or other serious conditions, others remain hospitalized primarily to receive IV antibiotics. Expanding the use of oral antibiotics in emergency departments should be pursued only if it can demonstrate comparable efficacy and safety to IV administration. Therefore this study will investigate the efficiency of primarily oral antibiotics in acutely admitted patients with proven or suspected infections. Additionally, the investigators will evaluate the safety of oral regimen for these patients.
CONDITIONS
Official Title
Intravenous Versus Oral Treatment of the Main Acute Infections
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Suspected respiratory tract infection, urinary tract infection, or cellulitis by the attending physician
- Planned or initiated intravenous antibiotic treatment
You will not qualify if you...
- Received more than two doses of intravenous antibiotics
- Systolic blood pressure less than 90 mmHg
- Nausea and/or vomiting more than once during the last 2 days
- Suspected significantly reduced gastrointestinal absorption
- Confirmed plasma-lactate greater than 2
- Pregnant or nursing
- Unable to give informed consent
- Severe immunodeficiency
- Urgent vital treatment needed
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Sygehus Sønderjylland
Aabenraa, Southern Denmark, Denmark, 6200
Actively Recruiting
2
Bispebjerg and Frederiksberg Hospital
Copenhagen, Denmark, 2400
Active, Not Recruiting
3
Nordsjællands Hospital
Copenhagen, Denmark
Actively Recruiting
4
Esbjerg and Grindsted Sygehus
Esbjerg, Denmark, 6700
Actively Recruiting
5
Herlev and Gentofte Hospital
Herlev, Denmark, 2730
Active, Not Recruiting
6
Amager and Hvidovre Hospital
Hvidovre, Denmark, 2650
Active, Not Recruiting
7
Sygehus Lillebælt
Kolding, Denmark, 6000
Actively Recruiting
Research Team
M
Mariana Bichuette Cartuliares
CONTACT
H
Helene Skjøt-Arkil
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here